ThinkCyte, a Tokyo, Japan- and Redwood City, CA-based biotechnology firm developing scientific instruments, secured $15M in the extension round, closing Series C at $32M.
Leading the round were SMBC Venture Capital No. 7 Investment Limited Partnership, KIRIN-GB Fund I L.P., and Japan Green Investment Corp. for Carbon Neutrality (JICN). Additionally, the business obtained a loan from Japan Finance Corporation. The fundraising round takes ThinkCyte’s total to $91 million.
The company plans to use the money to speed its worldwide commercial expansion as well as scale up production and manufacturing.
Read also- India-Based AGRIM has Secured $17.3 Million in Series B Round Funding
ThinkCyte is a biotechnology startup that was established in 2016 that creates scientific instruments for life science research, diagnostics, and treatment development. These instruments are built on integrated, multidisciplinary technologies.
The company’s flagship product, VisionSort, is an AI-based dual-mode fluorescence and morphometric cell sorting technology that has been embraced by significant biopharmaceutical businesses and academic institutions globally since its launch in June 2023.
Read also- Abu Dhabi-Based Hulexo has Secured Undisclosed Amount in Seed Round Funding
To further advance research, the company collaborates with international biopharmaceutical companies and academic research centers.
About ThinkCyte
ThinkCyte’s single-cell technology is a transformational tool for scientists and biomedical professionals to accelerate biological discoveries and develop new treatments and diagnostics using advanced hardware, machine learning, and biotechnology.
